Lataa...
Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient
BACKGROUND: Leptomeningeal disease (LMD) from melanoma is rapidly fatal with median overall survival between 6.9 weeks and 3.5 months. It is not known whether immune checkpoint inhibitors have a role in treating LMD. CASE PRESENTATION: We report a 33-year-old male patient who developed LMD from a BR...
Tallennettuna:
| Julkaisussa: | Immunotherapy |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Future Medicine Ltd
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7421879/ https://ncbi.nlm.nih.gov/pubmed/32571131 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/imt-2019-0004 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|